NVS
| Market cap | $203.64B |
|---|---|
| Enterprise value | $248.01B |
| Revenue | $45.572B |
|---|---|
| EBITDA | $20.211B |
| Income | $15.245B |
| Revenue Q/Q | -8.24% |
| Revenue Y/Y | N/A |
| P/E | 21.15 |
|---|---|
| Forward P/E | N/A |
| EV/Sales | 5.44 |
| EV/EBITDA | 12.27 |
| EV/EBIT | 23.42 |
| PEG | 5.33 |
| Price/Sales | 4.47 |
| P/FCF | 19.72 |
| Price/Book | 4.36 |
| Book/Share | 24.76 |
| Cash/Share | 8.73 |
| FCF yield | 5.07% |
| Volume | 1.378M / 1.078M |
|---|---|
| Relative vol. | 1.28 × |
| EPS | 5.11 |
|---|---|
| EPS Q/Q | -6.02% |
| Est. EPS Q/Q | -9.36% |
| Profit margin | 31.83% |
|---|---|
| Oper. margin | 22.70% |
| Gross margin | 73.27% |
| EBIT margin | 23.24% |
| EBITDA margin | 44.35% |
| Ret. on assets | 14.59% |
|---|---|
| Ret. on equity | 34.58% |
| ROIC | 8.89% |
| ROCE | 16.28% |
| Debt/Equity | 1.14 |
|---|---|
| Net debt/EBITDA | 3.10 |
| Current ratio | 0.90 |
| Quick ratio | 0.71 |
| Volatility | 1.06% |
|---|---|
| Beta | 0.36 |
| RSI | 68.00 |
|---|
| Insider ownership | 0.01% |
|---|---|
| Inst. ownership | 9.20% |
| Shares outst. | 2.190B |
|---|---|
| Shares float | 0.000 0.00% |
| Short % of float | 0.00% |
| Short ratio | 2.30 |
| Dividend | $3.78 |
|---|---|
| Dividend yield | 3.49% |
| Payout ratio | 73.92% |
| Payment date | N/A |
| Ex-dividend date | N/A |
| Earnings date | 18 Jul 2024 |
Sunday, 5 May 2024
|
|
| Questor: this medical stock is expensive – but worth paying for | |
Tuesday, 23 April 2024
|
|
| Novartis Extends Three-Day Stock Sprint With First-Quarter Beat And Raise | |
| UPDATE 2-Novartis lifts guidance after Q1 results beat expectations | |
Thursday, 18 April 2024
|
|
| US FDA mandates label updates on CAR-T cancer therapies | |
Sunday, 14 April 2024
|
|
| Antitrust fervor is gripping Washington and Silicon Valley. But lawsuits have been declining. | |
Saturday, 10 February 2024
|
|
| 30 Most Valuable Drug Companies in 2024 | |
Monday, 5 February 2024
|
|
| Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion | |
| UPDATE 1-Novartis to acquire cancer drug developer MorphoSys for $2.9 bln | |
Thursday, 1 February 2024
|
|
| Novartis AG Q4 2023 Earnings Call Transcript | |
| Company News for Feb 1, 2024 | |
Tuesday, 30 January 2024
|
|
| Top 15 Best-Selling Cancer Drugs | |
| 15 Best Annual Dividend Stocks To Buy Now | |
Wednesday, 24 January 2024
|
|
| 35 Richest Countries by Median Income | |
Monday, 22 January 2024
|
|
| US FDA requires 'boxed warning' for CAR-T cancer therapies | |
Thursday, 18 January 2024
|
|
| Novartis Stock Slides as Market Rises: Facts to Know Before You Trade | |
Thursday, 11 January 2024
|
|
| Novartis Pursuit of Cytokinetics Cools | |
Monday, 8 January 2024
|
|
| Cytokinetics Has Clawed Back 105% Over Seven Days. Now It Could Score A Buyout. | |
| Novartis in Advanced Talks to Buy Cytokinetics | |
| Cytokinetics Stock Jumps After Report of Possible Novartis Deal | |
Sunday, 7 January 2024
|
|
| Alphabet's Isomorphic Labs In Drug Discovery Deals With Eli Lilly, Novartis | |
Powered by
Robintrack.
Price target
Current $108.13
Average $105.80
Low $82
High $121
Dividends
| Ex-dividend date | N/A | Frequency | Annual | Annual dividend | +3.33% |
|---|---|---|---|---|---|
| Next dividend | N/A | Dividend yield | 3.49% | Growth period | 1 year |
| Last dividend date | Yield 3 years | 3.54% | Growth 3 years | +4.47% | |
| Last dividend | Yield 5 years | 3.54% | Growth 5 years | +3.11% |
| Insider | Age | Since | Compensation |
|---|---|---|---|
| Vasant Narasimhan (44) Chief Executive Officer and Member of the Executive Committee since 2018 | 44 | 2018 | $11,437,500 |
| James Bradner (48) President of the Novartis Institutes for BioMedical Research (NIBR) and Member of the Executive Committee since 2016 | 48 | 2016 | $6,308,280 |
| Harry Kirsch (55) Chief Financial Officer and Member of the Executive Committee since 2013 | 55 | 2013 | $6,079,860 |
| Dr. Vasant Narasimhan (45) Chief Exec. Officer | 45 | $5,083,825 | |
| John Tsai (53) Head of Global Drug Development, Chief Medical Office, and Member of the Executive Committee since 2018 | 53 | 2018 | $4,685,010 |
| Susanne Schaffert (53) CEO Novartis Oncology and Member of the Executive Committee since 2019 | 53 | 2019 | $4,577,530 |
| Steven Baert (46) Chief People, Organization Officer, and Member of the Executive Committee since 2014 | 46 | 2014 | $4,005,540 |
| Joerg Reinhardt (64) Independent Non-Executive Chairman of the Board since 2013 | 64 | 2013 | $3,804,370 |
| Richard Saynor (54) Chief Exec. Officer of S and oz | 54 | $3,795,369 | |
| Shannon Klinger (49) Group General Counsel and Member of the Executive Committee since 2018 | 49 | 2018 | $3,619,780 |
| Dr. James E. Bradner M.D. (49) Pres of Novartis Institutes for Biomedical Research | 49 | $3,203,052 | |
| Steffen Lang (53) Global Head of Novartis Technical Operations and Member of the Executive Committee since 2018 | 53 | 2018 | $3,142,800 |
| Susanne Schaffert Ph.D. (54) Pres of Novartis Oncology | 54 | $3,009,188 | |
| Daniel Vasella (66) Honorary Chairman of the Board | 66 | $2,977,760 | |
| Richard Saynor (53) Chief Executive Officer of S, oz, and Member of the Executive Committee since 2019 | 53 | 2019 | $2,752,730 |
| Harry Kirsch (56) Chief Financial Officer | 56 | $2,675,397 | |
| Bertrand Bodson (45) Chief Digital Officer and Member of the Executive Committee since 2018 | 45 | 2018 | $2,572,110 |
| Robert Weltevreden (51) Head of Novartis Business Services (NBS) and Member of the Executive Committee since 2018 | 51 | 2018 | $2,377,730 |
| Dr. John Tsai (54) Head of Global Drug Devel. and Chief Medical Officer | 54 | $2,300,154 | |
| Marie-France Tschudin (49) President of Novartis Pharmaceuticals and Member of the Executive Committee since 2019 | 49 | 2019 | $2,123,290 |
| Klaus Moosmayer (52) Chief Ethics, Risk, Compliance Officer, and Member of the Executive Committee since 2018 | 52 | 2018 | $2,117,370 |
| Marie-France Tschudin (50) Pres of Novartis Pharmaceuticals | 50 | $2,100,283 | |
| Steffen Lang Ph.D. (54) Global Head of Technical Operations | 54 | $2,019,072 | |
| Karen L. Hale (53) Chief Legal Officer | 53 | $1,975,742 | |
| Dr. John Tsai M.D. (54) Head of Global Drug Devel. and Chief Medical Officer | 54 | $1,871,536 | |
| Robert Weltevreden (52) Head of Customer and Technology Solutions | 52 | $1,566,356 | |
| Dr. Klaus Moosmayer Ph.D. (53) Chief Ethics, Risk, and Compliance Officer | 53 | $1,326,395 | |
| Dr. Robert Kowalski Pharm.D. (53) Chief People and Organization Officer | 53 | $1,136,895 | |
| Enrico Vanni (69) Independent Non-Executive Vice Chairman of the Board since 2013 | 69 | 2013 | $533,511 |
| Andreas von Planta (64) Non-Executive Independent Director since 2006 | 64 | 2006 | $464,373 |
| Srikant Datar (67) Non-Executive Independent Director since 2003 | 67 | 2003 | $460,000 |
| Elizabeth Doherty (63) Non-Executive Independent Director since 2016 | 63 | 2016 | $450,000 |
| Ann Fudge (69) Non-Executive Independent Director since 2008 | 69 | 2008 | $400,000 |
| Charles Sawyers (61) Non-Executive Independent Director since 2013 | 61 | 2013 | $360,000 |
| Nancy Andrews (62) Non-Executive Independent Director since 2015 | 62 | 2015 | $360,000 |
| Ton Buechner (55) Non-Executive Independent Director since 2016 | 55 | 2016 | $354,372 |
| William Winters (59) Non-Executive Independent Director since 2013 | 59 | 2013 | $353,333 |
| Frans van Houten (60) Non-Executive Independent Director since 2017 | 60 | 2017 | $320,001 |
| Patrice Bula (64) Non-Executive Independent Director since 2019 | 64 | 2019 | $271,040 |
| Simon Moroney (61) Director since 2020 | 61 | 2020 | |
| Bridgette Heller (58) Director since 2020 | 58 | 2020 | |
| Samir Shah | 2013 | ||
| Charlotte Pamer-Wieser | 2011 | ||
| Alex Krauer (70) Honorary Chairman of the Board | 70 |
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.
- Health Care > Pharmaceuticals
- Novartis AG, Lichtstrasse 35, Basel 4056, Switzerland
- 41 61 324 1111
- Investor relations
Dividends
| Ex-dividend date | N/A | Frequency | Annual | Annual dividend | +3.33% |
|---|---|---|---|---|---|
| Next dividend | N/A | Dividend yield | 3.49% | Growth period | 1 year |
| Last dividend date | Yield 3 years | 3.54% | Growth 3 years | +4.47% | |
| Last dividend | Yield 5 years | 3.54% | Growth 5 years | +3.11% |
Quarterly EPS estimates
Profit margin
Debt to assets
Cash flow
Balance sheet
XSLX
| (in millions USD) | 23 Apr 2024 | 31 Jan 2024 | |||
|---|---|---|---|---|---|
| Current assets | |||||
| Cash | $9,694 | $14,428 | |||
| Short term investments | $2,759 | $2,016 | |||
| Net receivables | $8,251 | $8,124 | |||
| Inventory | $5,743 | $5,913 | |||
| Other current assets | $2,759 | $2,016 | |||
| Total current assets | $26,447 | $30,481 | |||
| Long term investments | $67,887 | $69,464 | |||
| Property, plant & equipment | $9,200 | $9,514 | |||
| Goodwill | $23,063 | $23,341 | |||
| Intangible assets | $26,272 | $26,879 | |||
| Other assets | $5,038 | $3,155 | |||
| Total assets | $94,334 | $99,945 | |||
| Current liabilities | |||||
| Accounts payable | $4,062 | $4,926 | |||
| Short long term debt | $8,564 | $6,314 | |||
| Other current liabilities | $16,662 | $15,150 | |||
| Total current liabilities | $29,288 | $26,390 | |||
| Long term debt | $18,720 | $20,034 | |||
| Other liabilities | $4,259 | $4,523 | |||
| Minority interest | $81 | $83 | |||
| Total liabilities | $54,659 | $53,278 | |||
| Stockholders' equity | |||||
| Common stock | $2,044 | $2,053 | |||
| Retained earnings | |||||
| Treasury stock | -$17 | -$41 | |||
| Capital surplus | |||||
| Total stockholder equity | $39,675 | $46,667 | |||
| Net tangible assets | -$9,660 | -$3,553 | |||
| (in millions USD) | 2024 | 2023 | ||
|---|---|---|---|---|
| Current assets | ||||
| Cash | $14,428 | $18,973 | ||
| Short term investments | $2,016 | $1,869 | ||
| Net receivables | $8,124 | $8,893 | ||
| Inventory | $5,913 | $7,175 | ||
| Other current assets | $2,016 | $1,869 | ||
| Total current assets | $30,481 | $36,910 | ||
| Long term investments | $69,464 | $80,543 | ||
| Property, plant & equipment | $9,514 | $10,764 | ||
| Goodwill | $23,341 | $29,301 | ||
| Intangible assets | $26,879 | $31,644 | ||
| Other assets | $3,155 | $3,070 | ||
| Total assets | $99,945 | $117,453 | ||
| Current liabilities | ||||
| Accounts payable | $4,926 | $5,146 | ||
| Short long term debt | $6,314 | $6,127 | ||
| Other current liabilities | $15,150 | $17,383 | ||
| Total current liabilities | $26,390 | $28,656 | ||
| Long term debt | $20,034 | $21,782 | ||
| Other liabilities | $4,523 | $4,906 | ||
| Minority interest | $83 | $81 | ||
| Total liabilities | $53,278 | $58,111 | ||
| Stockholders' equity | ||||
| Common stock | $2,077 | $2,181 | ||
| Retained earnings | ||||
| Treasury stock | -$41 | -$92 | ||
| Capital surplus | ||||
| Total stockholder equity | $46,667 | $59,342 | ||
| Net tangible assets | -$3,553 | -$1,603 | ||
Income statement
| (in millions USD) | 23 Apr 2024 | 31 Jan 2024 | |||
|---|---|---|---|---|---|
| Revenue | |||||
| Total revenue | $12,120 | $7,424 | |||
| Cost of revenue | $3,096 | $1,083 | |||
| Gross profit | $9,024 | $6,341 | |||
| Operating activities | |||||
| Research & development | $2,421 | $2,126 | |||
| Selling, general & administrative | $2,840 | $2,297 | |||
| Total operating expenses | $9,025 | $5,092 | |||
| Operating income | $3,095 | $2,332 | |||
| Income from continuing operations | |||||
| Net other income | $249 | -$224 | |||
| EBIT | $3,344 | $2,108 | |||
| Income before tax | $3,129 | $2,062 | |||
| Income tax expense | $441 | -$386 | |||
| Minority interest | |||||
| Net income | |||||
| Net income | $2,688 | $8,480 | |||
| Income (for common shares) | $2,688 | $8,480 | |||
| (in millions USD) | 2024 | 2023 | ||
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $46,660 | $51,828 | ||
| Cost of revenue | $12,472 | $15,486 | ||
| Gross profit | $34,188 | $36,342 | ||
| Operating activities | ||||
| Research & development | $11,371 | $9,996 | ||
| Selling, general & administrative | $12,517 | $14,253 | ||
| Total operating expenses | $36,373 | $39,735 | ||
| Operating income | $10,287 | $12,093 | ||
| Income from continuing operations | ||||
| Net other income | ||||
| EBIT | $10,287 | $12,084 | ||
| Income before tax | $9,123 | $8,371 | ||
| Income tax expense | $551 | $1,416 | ||
| Minority interest | $4 | |||
| Net income | ||||
| Net income | $14,850 | $6,955 | ||
| Income (for common shares) | $14,850 | $6,955 | ||
Cash flows
| (in millions USD) | 23 Apr 2024 | 31 Jan 2024 | |||
|---|---|---|---|---|---|
| Net income | $2,688 | $8,480 | |||
| Operating activities | |||||
| Depreciation | $1,342 | $8,277 | |||
| Change in accounts receivable | $8,251 | $8,124 | |||
| Changes in inventory | $5,743 | $5,913 | |||
| Total cash flows from operations | $2,265 | $2,547 | |||
| Investing activities | |||||
| Capital expenditures | -$1,156 | -$783 | |||
| Investments | |||||
| Other cash flows from investing | |||||
| Total cash flows from investing | -$899 | -$1,760 | |||
| Financing activities | |||||
| Dividends paid | |||||
| Net borrowings | $14,831 | $9,904 | |||
| Other cash flows from financing | |||||
| Total cash flows from financing | -$5,164 | -$607 | |||
| Effect of exchange rate | |||||
| Change in cash and equivalents | $9,694 | $14,428 | |||
| (in millions USD) | 2024 | 2023 | ||
|---|---|---|---|---|
| Net income | $14,850 | $6,955 | ||
| Operating activities | ||||
| Depreciation | $8,277 | $7,181 | ||
| Change in accounts receivable | -$769 | $65 | ||
| Changes in inventory | -$1,262 | $509 | ||
| Total cash flows from operations | $14,458 | $14,236 | ||
| Investing activities | ||||
| Capital expenditures | -$2,753 | -$2,672 | ||
| Investments | ||||
| Other cash flows from investing | ||||
| Total cash flows from investing | $5,596 | $1,468 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Net borrowings | $9,904 | $7,067 | ||
| Other cash flows from financing | ||||
| Total cash flows from financing | -$14,278 | -$20,562 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$4,545 | -$9,356 | ||
Recent institutional transactions
| Quarter | Shareholder | Change |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|---|
| 2024 Q2 | Boston Common Asset Management |
+36.61%
|
170,871 | $18,287 |
| 2024 Q2 | Capital Market Strategies |
Opened
|
2,700 | $287,442 |
| 2024 Q2 | Kathmere Capital Management |
-10.51%
|
11,168 | $1,127,633 |
| 2024 Q2 | Thurston, Springer, Miller, Herd & Titak, Inc |
Opened
|
587 | $62,485 |
| 2024 Q2 | Cascade Investment Advisors |
+1.62%
|
22,610 | $2,407,061 |
| 2024 Q2 | Appleton Partners Inc/ma |
-4.92%
|
2,106 | $224 |
| 2024 Q2 | Marcum Wealth |
+1.30%
|
2,033 | $216,433 |
| 2024 Q1 | Magnetar |
Opened
|
1,906,046 | $184,371,830 |
| 2024 Q1 | Dodge & Cox |
-6.16%
|
12,353,985 | $1,195,000,969 |
| 2024 Q1 | Citigroup Inc |
+281.53%
|
916,164 | $88,620,527 |
Institutional shareholders
| Shareholder | Stake |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|
| Primecap Management Co/ca/ | 0.67% | 14,595,152 | |
| Dodge & Cox | 0.56% | 12,353,985 | |
| Morgan Stanley | 0.33% | 7,258,381 | |
| Dimensional Fund Advisors L.P. | 0.27% | 6,018,082 | |
| Franklin Resources Inc | 0.26% | 5,699,789 | |
| Bank Of America Corp de/ | 0.22% | 4,888,193 | |
| Wellington Management Group LL.P. | 0.21% | 4,589,350 | |
| Goldman Sachs Group Inc | 0.14% | 3,059,361 | |
| Renaissance Technologies | 0.13% | 2,838,082 | |
| Janus Henderson Group PLC | 0.12% | 2,568,728 |
Sign up